Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03154645 · ClinicalTrials.gov registry record · Phase 1
Altitude Sickness Prevention With Ibuprofen Relative to Acetazolamide and Treatment Efficacy
A Phase 1 study of Acute Mountain Sickness, sponsored by Grant S Lipman.
- Completed
- Registry status
- Phase 1
- Development phase
- 92
- Enrollment target
- 1
- Study location
NCT03154645: Completed Phase 1 study of Acute Mountain Sickness, sponsored by Grant S Lipman.
NCT03154645 is a Phase 1 study of Acute Mountain Sickness that has completed, run by Grant S Lipman. The registered enrollment target is 92 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (53% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03154645, a Phase 1 study of Acute Mountain Sickness, has completed, sponsored by Grant S Lipman.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 92 participants
- Enrollment target
- 1
- Study location
Study Summary
This double blind randomized trial will compare ibuprofen to acetazolamide for the prevention of acute mountain sickness. These drugs have never been directly compared for efficacy. The study population is hikers who are ascending at their own rate under their own power in a true hiking environment at the White Mountain Research Station, Owen Valley Lab (OVL) and Bancroft Station (BAR), Bancroft Peak, White Mountain, California.
Primary Outcome
incidence of acute mountain sickness by Lake Louise Questionnaire
Conditions Studied
Interventions
- DRUG Ibuprofen
- DRUG Acetazolamide
Study Locations (1)
California
- White Mountain Research Station - Bishop
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2017-08-12 |
| Est. Completion | 2017-10-01 |
| Phase | Phase 1 |
What the finished NCT03154645 record still lists
NCT03154645 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 92 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (53% higher).
The record links to 1 condition, with Acute Mountain Sickness appearing as the primary indexed condition, and to 2 interventions - of which Ibuprofen is the first listed.
NCT03154645 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT03154645 about?
NCT03154645 is a clinical study titled "Altitude Sickness Prevention With Ibuprofen Relative to Acetazolamide and Treatment Efficacy". This double blind randomized trial will compare ibuprofen to acetazolamide for the prevention of acute mountain sickness. These drugs have never been directly compared for efficacy. The study population is hikers who are ascending at their own rate under their own power in a true hiking environment ...
What is the current status of trial NCT03154645?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 92 participants. The study started on 2017-08-12. Estimated completion is 2017-10-01.
What conditions does trial NCT03154645 study?
This clinical trial studies the following conditions: Acute Mountain Sickness.
What interventions are being tested in trial NCT03154645?
The interventions under investigation include: Ibuprofen (DRUG), Acetazolamide (DRUG).
Who is sponsoring clinical trial NCT03154645?
This trial is sponsored by Grant S Lipman, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03154645 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Mountain Sickness
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03154645's enrollment target sits among peer trials
92 625th of 2000 higher than 1,375 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03184545 · 92 participants · Phase 3
Comparing the Outcome of Electrical Stimulation and Physical Therapy in Patellofemoral Pain Syndrome
- NCT04172532 · 92 participants · Phase 1
Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
- NCT04508088 · 92 participants
Skeletal Health and Bone Marrow Composition in Newly Diagnosed Adolescents With Crohn Disease
- NCT04840602 · 92 participants · Phase 2
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI